Unlock the potential of low-level laser therapy: A revolutionary approach to pain management

Pain, whether chronic or acute, is an undeniable aspect of the human experience. Its impact can extend far beyond the physical realm, affecting emotional well-being and overall quality of life.

Recent findings from Nuffield Health reveal a significant disparity in how pain affects women, with joint pain notably impacting emotional and physical health more profoundly for women than men. In fact, between 40% and 50% of women suffering from joint pain report adverse effects on emotional health and sleep quality.

Understanding low-level laser therapy

Traditionally, individuals grappling with pain have resorted to over-the-counter medications like nonsteroidal anti-inflammatory drugs (NSAIDs), such as Ibuprofen. However, these remedies often come with a host of adverse effects, particularly on gut health.

In contrast, low-level laser therapy (LLLT) operates on a fundamentally different principle. Utilizing specific light wavelengths, LLLT targets mitochondria, the powerhouses responsible for energy production within cells.

Research demonstrates LLLT rivals the efficacy of NSAIDs in pain relief, without the attendant risks. By harnessing the power of light energy, LLLT promotes cellular metabolism, DNA synthesis and signaling pathways critical for tissue repair and regeneration.

Erchonia’s low-level lasers employ precise wavelengths of light absorbed by mitochondria, facilitating increased ATP production and subsequent pain relief. This targeted approach provides therapeutic benefits, offering a safer, more holistic alternative for patients and healthcare providers alike.

Erchonia lasers for reducing pain from inflammation

When inflammation occurs, the body releases chemicals triggering blood vessels to dilate and leak fluid into tissues, resulting in swelling, pressure and nerve irritation, ultimately leading to pain.

Chronic inflammation poses a significant obstacle to healing, as it fosters the accumulation of free radicals and oxidative stress, damaging cells and impeding the recovery process.

Erchonia’s low-level lasers have the capacity to mitigate inflammation within the body by stimulating the production of new cells and blood vessels, reducing inflammation and alleviating pain. The following conditions might benefit from Erchonia’s LLLT:

• Arthritis
• Tendinitis
• Back, neck, shoulder and knee pain
• Carpal tunnel syndrome
• Tennis elbow
• Plantar fasciitis
• Fibromyalgia
• Temporomandibular joint disorder (TMJ)

The FDA has cleared Erchonia’s lasers for targeted pain relief in specific areas, such as the back, neck and bottom of the feet, as well as for whole-body pain.

In a recent study focusing on chronic low back pain, researchers evaluated the impact of Erchonia’s LLLT on a group of patients. Following eight 20-minute sessions over a four-week period, participants reported a ≥ 30% reduction in pain intensity, indicating the therapeutic potential of LLLT in managing musculoskeletal-related back pain.

Erchonia lasers for recovery

Pain management can be a challenge after surgery, and many people turn to prescription medications. Studies have shown Erchonia’s LLLT can reduce the need for prescription medication post-surgery and improve overall recovery time.

In 2022, it was reported 32% of births in the U.S. were cesarean (C-) section, with 80% of patients experiencing postoperative pain. Erchonia’s LLLT technology harnesses a low-frequency laser capable of being absorbed into the body’s tissues, resulting in less inflammation, better pain relief and enhanced tissue repair.

SERENA POON, CN, CHC, CHN, is a certified nutritionist and celebrity chef, Reiki Master and a wellness and longevity advisor. For more information, visit serenaloves.com.

References

1. Women shouldering the impact of joint pain, reporting greater emotional as well as physical impacts. Nuffield Health. https://www.nuffieldhealth.com/article/impact-of-joint-pain-on-women. Accessed April 11, 2024.
2. Januskewski J, et al. Efficacy of 635nm Red Low-Level Laser on Nociceptive Musculoskeletal Pain Compared to NSAIDS, Opioids, and Other Light Sources. 2020;17(2). Erchonia.
3. FDA Clears Low-Level Laser Device for ‘Whole Body’ Pain. July 18, 2019. Erchonia.
4. Berry TS, et al. Double-Blind-Study-Evaluating-FX-635-Laser-for-Treating-Lower-Back-Pain. February 15, 2020. Erchonia.
5. Osterman MJK. Changes in Primary and Repeat Cesarean Delivery: United States, 2016–2021. Vital Statistics Rapid Release. Number 21. July 2022. CDC.
6. Poursalehan S, et al. The Effect of Low-Level Laser on Postoperative Pain After Elective Cesarean Section. Anesth Pain Med. 2018; 8(6). NCBI.